Nucana (NCNA) has released an update.
NuCana plc has announced the discontinuation of its Phase 2 NuTide:323 study for colorectal cancer due to unlikely achievement of primary objectives, despite the treatment’s favorable safety profile. The company remains committed to cancer treatment improvement, focusing on ongoing studies such as NuTide:303 and NuTide:701, with promising data on NUC-7738 plus Pembrolizumab to be presented at the ESMO conference.
For further insights into NCNA stock, check out TipRanks’ Stock Analysis page.
